ReviewInflammopharmacology2025
Advancing osteoarthritis management: integrating new insights and addressing persistent roadblocks.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emerging pervasiveness of osteoarthritis (OA) in the general population has necessitated the exploration of the design and development of novel treatment options. The joint has been recognized as a separate entity undergoing degenerative processes, highlighting the multifaceted nature of osteoarthritis. OA is a widespread and disabling chronic joint condition, primarily affecting the elderly population. Despite incremental advances in our understanding of OA pathophysiology and the development of new treatment strategies, the long-term management of this complex disease remains a significant challenge. Emerging evidence highlights the central role of inflammatory markers progression of OA. This comprehensive review aims to synthesize the latest insights into OA disease mechanisms and explore how these advancements can be leveraged to improve clinical outcomes, while also addressing the persistent roadblocks that continue to hinder effective management. Furthermore, this review provides comprehensive insights into the novel anti-inflammatory compounds along with other developments in the field of osteoarthritis management.
Indexed as
Identifiers
40721701What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.